Celsius Therapeutics

Acquired

On a quest to leverage the power of single cell genomics

Cambridge, United States · Founded 2018 · $148.0M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$148.0M
Last Round
$83.0M Series BMar 2022
Rounds
2
Acquired by
AbbVieJun 2024 · $250.0M

About

Celsius Therapeutics was a biotechnology company that leveraged single-cell RNA sequencing and genomic analysis to identify novel drug targets and develop precision medicines for complex diseases including autoimmunity and cancer. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company built a human tissue-based platform combining scRNA-seq with machine learning to characterize disease biology at the cellular level. Celsius was acquired by AbbVie in June 2024.

Summary

Celsius Therapeutics is a Biotech company based in Cambridge, United States, founded in 2018. It has raised $148.0M in total across 2 rounds, most recently a $83.0M Series B round in Mar 2022. Investors include Casdin Capital, Third Rock Ventures and AbbVie Ventures.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionJun 2024

Sign up to see all 3 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Celsius Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/celsius-therapeutics"><img src="https://indexed.vc/api/badge/company/celsius-therapeutics" alt="Celsius Therapeutics on Indexed.vc" width="260" height="76" /></a>